Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans

8 Jun 2012

Abstract excerpt

Type II endometrial carcinomas are a highly aggressive group of tumour subtypes that are frequently associated with inactivation of the TP53 tumour suppressor gene. We show that mice with endometrium-specific deletion of Trp53 initially exhibited histological changes that are identical to known precursor lesions of type II endometrial carcinomas in humans and later developed carcinomas representing all type II...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Cancer Cells and Metastasis
Share to Endometrial and Cervical Cancer Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22678923
DOI: 10.1002/emmm.201101063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humansPMID 22678923Read ↗

Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.Semantic proximity Read ↗

<i>Lkb1</i>inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapySemantic proximity Read ↗

Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.Semantic proximity Read ↗

<i>In vivo</i> intra-uterine delivery of TAT-fused Cre recombinase and CRISPR/Cas9 editing unveil histopathology of Pten/p53-deficient endometrial cancersSemantic proximity Read ↗

Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice.Semantic proximity Read ↗

A New Type of Endometrial Cancer Models in Mice Revealing the Functional Roles of Genetic Drivers and Exploring their Susceptibilities.Semantic proximity Read ↗

Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activitiesSemantic proximity Read ↗

<i>Pten</i> and <i>Dicer1</i> loss causes poorly-differentiated endometrial adenocarcinoma in miceSemantic proximity Read ↗

LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies.Semantic proximity Read ↗

Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.Semantic proximity Read ↗

Conditional abrogation of transforming growth factor-β receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.Semantic proximity Read ↗

Inactivation of <i>Tp53</i> and <i>Pten</i> drives rapid development of pleural and peritoneal malignant mesotheliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.